Trial Profile
A multiple ascending dose of AP-325 in healthy male subjects
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2017
Price :
$35
*
At a glance
- Drugs AP 325 (Primary)
- Indications Neuropathic pain; Spinal cord injuries
- Focus Adverse reactions; Therapeutic Use
- Sponsors Algiax Pharmaceuticals
- 04 Aug 2017 New trial record